Recently, Gecell Therapeutics is awarded a Chinese national invention patent in the field of genome editing technology. This approved patent focuses on transposon-mediated knock-in of large-sized DNA into specific sites of genome, which effectively solves the technical difficulties in the industry and provides new ideas and directions for the further development of genome editing technology. This important achievement is the crystallization of the long-term in-depth exploration and continuous innovation of the company's R & D team, embodying the wisdom and hard work of team members.

Gecell Therapeutics has always regarded innovation as the core driving force for growth of the company and continued to invest in the R&D to build a first-tier technological innovation system. By continuously improving the R&D process and strengthening collaborations with universities and scientific research institutions, Gecell attracted outstanding talents and formed a high-quality and innovative R&D team. It is this persistent pursuit of innovation that has enabled the company to maintain a leading position in the field and continuously launch competitive therapeutics for diseases.

The approval of this patent is of great significance to the company. It upgrades the company's core technology platform and enhances the core competitiveness of the company's portfolios. Meanwhile, this achievement will also inspire all employees to continue to uphold the spirit of innovation, explore new ideas and develop new therapeutics, and inject new impetus into the company's sustainable development.

Looking to the future, Gecell will take this patent approval as an opportunity to continue technology innovation, continuously improve first-in-class drug development capabilities, actively promote the transformation and application of patented technologies, and take technological innovation as the guide to make greater contributions.